Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[3]  Keith A. Johnson,et al.  Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease , 2013, Neurobiology of Aging.

[4]  B. Winblad,et al.  How can elderly apolipoprotein E ε4 carriers remain free from dementia? , 2013, Neurobiology of Aging.

[5]  N. Fitz,et al.  Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice , 2012, The Journal of Neuroscience.

[6]  D. Geschwind,et al.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. , 2012, Archives of neurology.

[7]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[8]  K. Garai,et al.  Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer’s disease , 2012, Proceedings of the National Academy of Sciences.

[9]  M. Nalls,et al.  A large study reveals no association between APOE and Parkinson's disease , 2012, Neurobiology of Disease.

[10]  Mark A Mintun,et al.  Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. , 2012, Archives of neurology.

[11]  R. Mrak,et al.  Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience , 2012, BMC Medicine.

[12]  Y. Pi,et al.  Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: A meta-analysis , 2012, Neuroscience Letters.

[13]  A. Gillespie,et al.  Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Aβ Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice , 2012, The Journal of Neuroscience.

[14]  Andrew R. Bender,et al.  Age-related differences in memory and executive functions in healthy APOE ɛ4 carriers: The contribution of individual differences in prefrontal volumes and systolic blood pressure , 2012, Neuropsychologia.

[15]  Mirjam I. Geerlings,et al.  APOE ε4 differentially influences change in memory performance depending on age. The SMART-MR study , 2012, Neurobiology of Aging.

[16]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[17]  D. Alkon,et al.  Apolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase Cϵ , 2012, The Journal of Biological Chemistry.

[18]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[19]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[20]  Angela R. Laird,et al.  Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease , 2011, Neurology research international.

[21]  F. Gage,et al.  Adult hippocampal neurogenesis and its role in Alzheimer's disease , 2011, Molecular Neurodegeneration.

[22]  R. Mahley,et al.  Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.

[23]  D. Holtzman,et al.  Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.

[24]  T. Montine,et al.  Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease , 2011, Current Opinion in Neurobiology.

[25]  Kelly O'Keefe,et al.  Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.

[26]  J. Slaets,et al.  The Association of APOE Genotype with Cognitive Function in Persons Aged 35 Years or Older , 2011, PloS one.

[27]  Gui-rong Zhang,et al.  ApoE is required for maintenance of the dentate gyrus neural progenitor pool , 2011, Development.

[28]  Prashanthi Vemuri,et al.  Effect of APOE ε4 status on intrinsic network connectivity in cognitively normal elderly subjects. , 2011, Archives of neurology.

[29]  B. Hyman,et al.  Alzheimer's disease: synapses gone cold , 2011, Molecular Neurodegeneration.

[30]  Jianglei Chen,et al.  Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions , 2011, Proceedings of the National Academy of Sciences.

[31]  David M Holtzman,et al.  Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. , 2011, Archives of neurology.

[32]  C. Enzinger,et al.  APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study , 2011, The Lancet Neurology.

[33]  A. Blokland,et al.  Liver X receptor activation restores memory in aged AD mice without reducing amyloid , 2011, Neurobiology of Aging.

[34]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[35]  F. Panza,et al.  The APOE gene locus in frontotemporal dementia and primary progressive aphasia. , 2011, Archives of neurology.

[36]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[37]  K. Bales,et al.  Reduced levels of human apoE4 protein in an animal model of cognitive impairment , 2011, Neurobiology of Aging.

[38]  Hui Zheng,et al.  Biology and pathophysiology of the amyloid precursor protein , 2011, Molecular Neurodegeneration.

[39]  S. Rapcsak,et al.  Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers , 2011, Neurology.

[40]  P. Visser,et al.  Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  M. York,et al.  Does apolipoprotein E genotype modify the clinical expression of ALS? , 2011, European Journal of Neurology.

[42]  C. Rowe,et al.  Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.

[43]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[44]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[45]  S. D. Han,et al.  The Apolipoprotein E Antagonistic Pleiotropy Hypothesis: Review and Recommendations , 2011, International journal of Alzheimer's disease.

[46]  G. Bu,et al.  Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-β Uptake , 2011, The Journal of Neuroscience.

[47]  J. Stockman,et al.  Longitudinal Modeling of Age-Related Memory Decline and the APOE ɛ4 Effect , 2011 .

[48]  Bruce Fischl,et al.  Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. , 2011, Journal of Alzheimer's disease : JAD.

[49]  S. D. Moore,et al.  Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2 , 2010, Neuroscience.

[50]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[51]  Sachin Dixit,et al.  APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 , 2010, The Journal of Neuroscience.

[52]  Xianlin Han,et al.  Neuronal LRP1 Knockout in Adult Mice Leads to Impaired Brain Lipid Metabolism and Progressive, Age-Dependent Synapse Loss and Neurodegeneration , 2010, The Journal of Neuroscience.

[53]  X. Estivill,et al.  Variants at APOE influence risk of deep and lobar intracerebral hemorrhage , 2010, Annals of neurology.

[54]  Yadong Huang,et al.  Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice , 2010, The Journal of Neuroscience.

[55]  D. Brody,et al.  New perspectives on amyloid-beta dynamics after acute brain injury: moving between experimental approaches and studies in the human brain. , 2010, Archives of neurology.

[56]  Ronald C. Petersen,et al.  Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment , 2010, Alzheimer's & Dementia.

[57]  S. Kanba,et al.  Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.

[58]  C. Wellington,et al.  ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice* , 2010, The Journal of Biological Chemistry.

[59]  L. Mucke,et al.  Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. , 2010, The American journal of pathology.

[60]  C. Colton,et al.  An Apolipoprotein E-Mimetic Stimulates Axonal Regeneration and Remyelination after Peripheral Nerve Injury , 2010, Journal of Pharmacology and Experimental Therapeutics.

[61]  R. Sperling,et al.  Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline , 2010, Neurology.

[62]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[63]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[64]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[65]  A D Roses,et al.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease , 2009, The Pharmacogenomics Journal.

[66]  S. de Santi,et al.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. , 2010, Journal of Alzheimer's disease : JAD.

[67]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[68]  D. Holtzman,et al.  Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.

[69]  R. Mahley,et al.  GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. , 2009, Cell stem cell.

[70]  E. Weeber,et al.  ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo , 2009, The Journal of Neuroscience.

[71]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[72]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[73]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[74]  N. Filippini,et al.  Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.

[75]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[76]  F. Liu,et al.  Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.

[77]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[78]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[79]  Adam Gazzaley,et al.  Clinical‐neuroimaging characteristics of dysexecutive mild cognitive impairment , 2009, Annals of neurology.

[80]  K. Weisgraber,et al.  Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure* , 2009, Journal of Biological Chemistry.

[81]  D. Berlau,et al.  APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.

[82]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[83]  E. Tolosa,et al.  Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease , 2008, Neuroscience Letters.

[84]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[85]  Dean C. Delis,et al.  Decreased Cognition in Children with Risk Factors for Alzheimer's Disease , 2008, Biological Psychiatry.

[86]  M. Pangalos,et al.  Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.

[87]  K. Jellinger.  Morphologic diagnosis of “vascular dementia” — A critical update , 2008, Journal of the Neurological Sciences.

[88]  J. Jolles,et al.  The Association between APOE Genotype and Memory Dysfunction in Subjects with Mild Cognitive Impairment Is Related to Age and Alzheimer Pathology , 2008, Dementia and Geriatric Cognitive Disorders.

[89]  D. Selkoe,et al.  P4-209: Direct and potent regulation of γ-secretase by its lipid microenvironment , 2008, Alzheimer's & Dementia.

[90]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[91]  J. Brandt,et al.  APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease , 2008, Neurology.

[92]  Sterling C. Johnson,et al.  Magnetic Resonance Imaging Characterization of Brain Structure and Function in Mild Cognitive Impairment: A Review , 2008, Journal of the American Geriatrics Society.

[93]  J. Jia,et al.  Meta-analysis of APOE4 allele and outcome after traumatic brain injury. , 2008, Journal of neurotrauma.

[94]  Anders M. Fjell,et al.  Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E ɛ4 , 2008, Neurobiology of Aging.

[95]  T. Rea,et al.  NSAID use and dementia risk in the Cardiovascular Health Study* , 2008, Neurology.

[96]  L. Kuller,et al.  Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. , 2008, Archives of neurology.

[97]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[98]  H. Schipper,et al.  Oxysterols, cholesterol homeostasis, and Alzheimer disease , 2007, Journal of neurochemistry.

[99]  Eric M Reiman,et al.  Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. , 2007, Archives of neurology.

[100]  W. Poon,et al.  Meta-analysis of APOE genotype and subarachnoid hemorrhage , 2007, Neurology.

[101]  Peter Boesiger,et al.  Better Memory and Neural Efficiency in Young Apolipoprotein E ε4 Carriers , 2007 .

[102]  A. Fleisher,et al.  Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment , 2007, Neurology.

[103]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[104]  Edu,et al.  Molecular Neurodegeneration Apolipoprotein E Levels in Cerebrospinal Fluid and the Effects of Abca1 Polymorphisms , 2022 .

[105]  T. Comery,et al.  The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease , 2007, Molecular and Cellular Neuroscience.

[106]  D. Quartermain,et al.  Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease , 2006, Proceedings of the National Academy of Sciences.

[107]  J. Herz,et al.  Reelin, lipoprotein receptors and synaptic plasticity , 2006, Nature Reviews Neuroscience.

[108]  C. Colton,et al.  Apolipoprotein E-Derived Peptides Ameliorate Clinical Disability and Inflammatory Infiltrates into the Spinal Cord in a Murine Model of Multiple Sclerosis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[109]  Henrik Zetterberg,et al.  Alzheimer's disease , 2006, The Lancet.

[110]  Henrik Zetterberg,et al.  Plasma Aβ in Alzheimer's disease—up or down? , 2006, The Lancet Neurology.

[111]  B. Gmeiner,et al.  Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. , 2006, Biochimie.

[112]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[114]  Yaakov Stern,et al.  fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease , 2005, Neurology.

[115]  J. Troncoso,et al.  Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases , 2005, Neurobiology of Aging.

[116]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[117]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[118]  S. D. Moore,et al.  Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology , 2005, Neurobiology of Disease.

[119]  A. Saunders,et al.  Increased amyloid , 8-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease ( phenotype / APOE 4 gene ) , 2005 .

[120]  H. Przuntek,et al.  Apolipoprotein E genotypes do not influence the age of onset in Huntington’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[121]  H C Charles,et al.  Impact of APOE in mild cognitive impairment , 2004, Neurology.

[122]  B. Winblad,et al.  APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging , 2004, Neurology.

[123]  Philip Scheltens,et al.  Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment , 2004, Neurology.

[124]  P. Scheltens,et al.  Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[125]  Henrik Zetterberg,et al.  APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.

[126]  L. Baxter,et al.  Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele , 2004, Neurology.

[127]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[128]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[129]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[130]  Kaj Blennow,et al.  Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid , 2000, Neurochemical Research.

[131]  Robert Perry,et al.  Dementia with Lewy Bodies , 2007, Seminars in neurology.

[132]  D. Holtzman,et al.  Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients , 2003, Neuroscience.

[133]  M. Vitek,et al.  APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response* , 2003, Journal of Biological Chemistry.

[134]  S Rabe-Hesketh,et al.  Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication , 2003, Journal of neurology, neurosurgery, and psychiatry.

[135]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[136]  T. Uchihara,et al.  Increased Expression of Neuronal Apolipoprotein E in Human Brain With Cerebral Infarction , 2003, Stroke.

[137]  R. Pearlstein,et al.  Protective effect of apolipoprotein E-mimetic peptides on N-methyl-d-aspartate excitotoxicity in primary rat neuronal–glial cell cultures , 2003, Neuroscience.

[138]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[139]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[140]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[141]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[142]  C. Göritz,et al.  CNS synaptogenesis promoted by glia-derived cholesterol. , 2001, Science.

[143]  G. Getz,et al.  Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses , 2001, Neurochemistry International.

[144]  Hiroaki Kazui,et al.  Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer’s disease , 2001, Neurology.

[145]  D. Laskowitz,et al.  Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response , 2001, Journal of Neuroimmunology.

[146]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[147]  D. Levy,et al.  Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. , 2001, Atherosclerosis.

[148]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[149]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[150]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[151]  D. Holtzman,et al.  Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E , 2000, Neurobiology of Aging.

[152]  C. Jonker,et al.  APOE-ε4 is associated with memory decline in cognitively impaired elderly , 2000, Neurology.

[153]  A. Takeshita,et al.  Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. , 2000, Human molecular genetics.

[154]  S. Lovestone,et al.  The association between APOE and dementia does not seem to be mediated by vascular factors , 2000, Neurology.

[155]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[156]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[157]  W. Jagust,et al.  The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .

[158]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[159]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[160]  Daniel Bandy,et al.  Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease , 1998, Annals of neurology.

[161]  Mann,et al.  Amyloid β protein (Aβ) deposition in dementia with Lewy bodies: predominance of Aβ42(43) and paucity of Aβ40 compared with sporadic Alzheimer’s disease , 1998 .

[162]  J. Hardy,et al.  ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. , 1998, American journal of medical genetics.

[163]  E G Tangalos,et al.  Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer's disease but not in healthy control subjects , 1998, Neurology.

[164]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[165]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[166]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[167]  E. Feskens,et al.  Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. , 1996, Stroke.

[168]  Bradley T. Hyman,et al.  Apolipoprotein E ε4 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy , 1996 .

[169]  L. Thal,et al.  Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease , 1996, Neurology.

[170]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[171]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[172]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[173]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[174]  D. Graham,et al.  Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury , 1995, Nature Medicine.

[175]  S. Wilton,et al.  Apolipoprotein E and Alzheimer's disease , 1995 .

[176]  E. Perry,et al.  Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. , 1994, The American journal of pathology.

[177]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[178]  M. Rossor,et al.  Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. , 1994, Human molecular genetics.

[179]  C. Gottfries,et al.  Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II) , 1994, Journal of neurochemistry.

[180]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[181]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[182]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[183]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[184]  H. Vinters.  Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.